BSEInsider Trading / SAST7h ago · 25 Sept 2026, 12:23 pm
Intimation of closure of Trading Window wef October 1, 2026
Fischer Medical Ventures Ltd · 524743
✦ AI Summary
Fischer Medical Ventures Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of un-audited financial results for the quarter ended September 30, 2026, as per the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Fischer Medical Ventures Ltd - 524743 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
34f34c5b-21a7-4697-aca6-69cd150d422f.pdf
View document text
FISCHER MEDICAL VENTURES LIMITED
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548
Date: 25/09/2026
To To
BSE Limited National Stock Exchange of India Ltd. Exchange
Corporate Relationship Department Plaza, 5tll floor
25th Floor, P J Towers Plot No. C/ 1, G Block,
Dalal Street, Fort, Bandra-Kurla Complex Bandra (E),
Mumbai – 400 001 Mumbai - 400 051
Scrip Code: 524743 NSE Symbol: FISCHER
Dear Sir / Madam,
Sub: Closure of Trading Window
This is to inform that, as per the Company's code of conduct for Prohibition of Insider Trading and
pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing
in the Company’s equity shares by the Promoters /Directors / Designated persons will remain closed
from October 01, 2026 till 48 hours after the declaration of Un-Audited Financial Results for the quarter
ended September 30, 2026.
Intimation regarding the notice of Board Meeting to be held to consider and approve the Un-Audited
Financial Results for the quarter ended September 30, 2026 shall be sent separately to the Stock
Exchanges.
Further, the designated persons and their immediate relatives have been intimated not to trade in the
securities of the Company during the above said period of closure of trading window.
This is for your kind information and records.
Kindly acknowledge receipt.
Thanking You,
Yours Truly,
For FISCHER MEDICAL VENTURES LIMITED
BALAJI GANDLA
COMPANY SECRETARY & COMPLIANCE OFFICER
Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006